Ray Therapeutics

Focus: Ray Therapeutics is a pre-revenue biotech focused on optogenetic gene therapy, a cutting-edge approach to treating inherited retinal diseases and other rare conditions. The company is in early clinical stages with a lean, innovation-focused operating model.

Rare Diseases Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Ray Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Ray Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profou

Retinitis Pigmentosa

N/A

Clinical Trials (1)

NCT07502664Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

N/A

Help build intelligence for Ray Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering optogenetic gene therapy platform—a novel modality with significant intellectual property potential and first-mover advantage in inherited retinal disease
Early-stage environment offers direct impact on drug development decisions and exposure to translational research from bench to clinic
Focused pipeline in high-unmet-need areas (Stargardt disease, retinitis pigmentosa) with regulatory pathways accelerated by rare disease status

Watch Out For

No current job openings and undisclosed funding/employee count create uncertainty about near-term hiring and financial runway
Early clinical stage (Phase 1/2 maximum) means 5-7+ years to potential meaningful clinical data, requiring patience for career milestones
Lack of public financials, revenue, or exit timeline increases execution and funding risk relative to larger or later-stage peers

Generated by Claude from Ray Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients

Retinitis Pigmentosa

N/A

Clinical Trials (1)

NCT06375239Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

N/A

Intravenous

Prostate Cancer

Phase 1

RTx-015

Retinitis Pigmentosa

Phase 1

Clinical Trials (1)

NCT06460844Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)

Phase 1

RTx-021

Stargardt Disease

Phase 1/2

Clinical Trials (1)

NCT07439887Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Ophthalmology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Ophthalmology

2 pipeline

Marketed

Pipeline